HealthKick Podcast: PTX partners with the US’s largest cancer centre on personalised treatment
Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up...
Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up...
Prescient will join with the US’s largest cancer centre with the goal of creating best-in-class,...
Clinical stage oncology company Prescient Therapeutics to progress its deep pipeline of innovative cancer therapies...
Prescient has entered a deal with the manufacturing arm of the world-renowned QIMR Berghofer Medical...
It’s quarterlies season as the ASX market announcements page becomes increasingly flooded with lodgements. The...
The granting of an Orphan Drug Designation by the US FDA will grant PTX-100 market...
Prescient is continuing to be a powerful force in the burgeoning personalised cancer treatment therapy...
According to the World Health Organisation, cancer accounted for nearly 10 million deaths in 2020,...
Strong early indicators for the PTX-100 treatment give Prescient multiple pathways to market, as it...

This investor centre was built by Reach Markets
©2025 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.